{"id":1399,"date":"2025-06-16T10:41:37","date_gmt":"2025-06-16T10:41:37","guid":{"rendered":"https:\/\/lifesciences.enago.com\/blogs\/?p=1399"},"modified":"2025-07-31T16:05:58","modified_gmt":"2025-07-31T16:05:58","slug":"the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases","status":"publish","type":"post","link":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases","title":{"rendered":"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases"},"content":{"rendered":"<h2 data-start=\"777\" data-end=\"799\">Key Takeaways<\/h2>\n<ul data-start=\"800\" data-end=\"1325\">\n<li data-start=\"800\" data-end=\"881\">\n<p data-start=\"802\" data-end=\"881\"><strong data-start=\"805\" data-end=\"879\">Orphan drugs are scientifically powerful\u2014but financially overwhelming.<\/strong><\/p>\n<\/li>\n<li data-start=\"882\" data-end=\"969\">\n<p data-start=\"884\" data-end=\"969\"><strong data-start=\"887\" data-end=\"967\">Access is nearly nonexistent in LMICs due to high costs and import barriers.<\/strong><\/p>\n<\/li>\n<li data-start=\"970\" data-end=\"1061\">\n<p data-start=\"972\" data-end=\"1061\"><strong data-start=\"975\" data-end=\"995\">Ethical tensions<\/strong> include affordability, fairness, and healthcare prioritization.<\/p>\n<\/li>\n<li data-start=\"1062\" data-end=\"1157\">\n<p data-start=\"1064\" data-end=\"1157\"><strong data-start=\"1067\" data-end=\"1087\">Policy solutions<\/strong>: value-based pricing, public-private R&amp;D, and income-based pricing.<\/p>\n<\/li>\n<li data-start=\"1158\" data-end=\"1247\">\n<p data-start=\"1160\" data-end=\"1247\"><strong data-start=\"1163\" data-end=\"1202\">Better data and real-world evidence<\/strong> are essential for fair pricing and access.<\/p>\n<\/li>\n<li data-start=\"1248\" data-end=\"1325\">\n<p data-start=\"1250\" data-end=\"1325\"><strong data-start=\"1253\" data-end=\"1283\">A global compact is needed<\/strong> to align innovation with health equity.<\/p>\n<\/li>\n<\/ul>\n<h2 data-start=\"83\" data-end=\"125\">Executive Summary<\/h2>\n<p data-start=\"126\" data-end=\"770\">Orphan drugs\u2014treatments for rare diseases\u2014offer life-changing breakthroughs but at extreme costs, often over $300,000 to $4 million per patient. This creates a global access crisis: while innovation surges, affordability and equity lag, especially in low- and middle-income countries where most patients are excluded. As pricing models strain healthcare systems, urgent reforms are needed to balance innovation with access. Solutions like value-based pricing, transparent R&amp;D, and global tiered pricing offer a path forward. The WHO\u2019s Rare Disease Framework calls for coordinated action to make rare disease care more inclusive and sustainable.<\/p>\n<h2 data-start=\"126\" data-end=\"770\">The Ethical Dilemma of Orphan Drugs<\/h2>\n<p>In the realm of modern medicine, few challenges are as complex\u2014and as ethically fraught\u2014as the treatment of rare diseases. Affecting <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9632971\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">3.5% to 5.9%<\/a> of the global population, rare diseases present a dual narrative: one of groundbreaking scientific innovation, and another of escalating economic strain. At the heart of this tension are orphan drugs\u2014high-cost therapies designed for conditions that afflict fewer than 1 in 2,000 people.<\/p>\n<p>These therapies hold remarkable promise, often delivering life-altering, and in some cases curative, outcomes for patients who previously had no treatment options. Yet with <a href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/prices-new-us-drugs-doubled-4-years-focus-rare-disease-grows-2025-05-22\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">annual prices<\/a> often exceeding $300,000\u2014and in some cases, reaching as high as $4 million\u2014these treatments expose a fundamental paradox: how can society support the cost of compassionate innovation without compromising healthcare equity?<\/p>\n<h2>The Economics of Rarity: A Market Built on Exceptions<\/h2>\n<p>Yet this growth is built on fragile economic underpinnings. The development of an orphan drug can cost up to $1.5 billion\u2014similar to more common medications\u2014but the return on investment must be extracted from far smaller patient populations. This dynamic has created an \u201cinverse pricing model\u201d\u2014the fewer the patients, the higher the price. <a href=\"https:\/\/www.rarediseases.in\/us-fda-approved-hemgenix-to-cost-rs-28-52-crore\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">Gene therapies<\/a> for hemophilia B and spinal muscular atrophy can exceed $3.5 million per patient, while CAR T-cell therapies frequently top $400,000 per infusion.<\/p>\n<p>Companies often justify these prices by citing scientific complexity and long-term cost savings\u2014such as reduced hospitalizations or one-time cures. However, critics argue that industry-reported R&amp;D expenditures are often opaque and potentially inflated.<\/p>\n<h2>Structural Barriers in Low- and Middle-Income Countries (LMICs)<\/h2>\n<p>Orphan drugs are largely <a href=\"https:\/\/www.ispor.org\/docs\/default-source\/euro2022\/isporeu22brownlmic-orphan-drugsv2-pdf.pdf?sfvrsn=ef541866_0\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">inaccessible<\/a> in low- and middle-income countries (LMICs). Studies show they have a very limited presence in middle-income countries and are virtually absent in low-income countries, leaving most patients with rare diseases in these regions without access to life-saving treatments.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-1402 size-full\" src=\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/qqq-e1750055848122.png\" alt=\"\" width=\"781\" height=\"326\" srcset=\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/qqq-e1750055848122.png 781w, https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/qqq-e1750055848122-300x125.png 300w, https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/qqq-e1750055848122-768x321.png 768w\" sizes=\"auto, (max-width: 781px) 100vw, 781px\" \/><\/p>\n<h6><strong>Orphan Drug Availability Across Country Income Groups.<\/strong> This graph highlights the limited availability and delayed access to orphan drugs in low- and middle-income countries (LMICs), underscoring urgent policy and pricing reforms. Source: <a style=\"text-align: center; text-transform: inherit;\" href=\"https:\/\/www.ispor.org\/docs\/default-source\/euro2022\/isporeu22brownlmic-orphan-drugsv2-pdf.pdf?sfvrsn=ef541866_0\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">Brown D, <em data-start=\"300\" data-end=\"323\">Orphan Drugs in LMICs<\/em>, ISPOR Europe 2022<\/a><span style=\"text-align: center; text-transform: inherit;\">.<\/span><\/h6>\n<p>The <a href=\"https:\/\/www.rarediseases.in\/policy-hurdles-create-high-costs-for-orphan-drugs-in-india\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">financial burden<\/a> is especially crushing in LMICs. In India, for example, therapies like trientine for Wilson\u2019s disease or eliglustat for Gaucher\u2019s disease cost more than \u20b91.6 crore (~$192,000) annually. As a result, more than 95% of patients are effectively excluded from access. Such structural inequities render even approved therapies inaccessible, reinforcing the need for global strategies that center both innovation and inclusivity.<\/p>\n<p>The following table helps clarify how structural economic barriers in the orphan drug market translate directly into steep costs and limited access for patients, especially in low- and middle-income countries:<\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>Barrier<\/strong><\/td>\n<td><strong>Economic Mechanism<\/strong><\/td>\n<td><strong>Impact on Patients<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Limited economies of scale<\/td>\n<td>High fixed R&amp;D costs spread across few users<\/td>\n<td><a href=\"https:\/\/www.ihealthcareanalyst.com\/orphan-drugs-valuation-overview-market-pricing\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">Annual costs &gt; $200,000<\/a><\/td>\n<\/tr>\n<tr>\n<td>Monopoly pricing<\/td>\n<td>Regulatory exclusivity for orphan drugs<\/td>\n<td><a href=\"https:\/\/icer.org\/wp-content\/uploads\/2022\/04\/ICER-White-Paper_The-Next-Generation-of-Rare-Disease-Drug-Policy_040722.pdf\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">No competition; no generics<\/a><\/td>\n<\/tr>\n<tr>\n<td>Importation markups<\/td>\n<td>Lack of local production<\/td>\n<td><a href=\"https:\/\/www.rarediseases.in\/made-in-india-missing-in-india-the-orphan-drug-access-challenge\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">300\u2013500% increase in end-user costs<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>The Ethical Crossroads: Innovation vs. Access<\/h2>\n<p>As healthcare budgets tighten and gene therapies proliferate, decision-makers face existential questions: Should a treatment for 100 people cost 100 times more per capita than one for 10,000? What happens when cures exist, but only for those who can afford them?<\/p>\n<p>The ethical dilemmas are stark:<\/p>\n<ul>\n<li><strong>Financial toxicity<\/strong>: A <a href=\"https:\/\/www.ajmc.com\/view\/poor-health-related-quality-of-life-many-burdens-in-rare-diseases-study-finds\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">recent survey<\/a> found that even with insurance, about one-quarter of rare disease patients in the U.S. face annual out-of-pocket healthcare costs exceeding $3,000, with many also reporting significant financial strain, barriers to care, and poor health-related quality of life as a result.<\/li>\n<li><strong>Geographic disparities<\/strong>: More than 95% of approved orphan drugs remain <a href=\"https:\/\/www.ispor.org\/docs\/default-source\/euro2022\/isporeu22brownlmic-orphan-drugsv2-pdf.pdf?sfvrsn=ef541866_0\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">unavailable in LMICs<\/a>.<\/li>\n<li><strong>Intergenerational tension<\/strong>: High-cost pediatric therapies raise difficult questions about opportunity <a href=\"https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017-1.pdf\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">costs and public spending priorities<\/a>.<\/li>\n<\/ul>\n<h2>Policy Innovations and Market-Based Solutions<\/h2>\n<p>Addressing the orphan drug paradox requires more than philanthropy\u2014it demands structural reform. Promising models include:<\/p>\n<ol>\n<li><strong> Value-Based and Performance-Linked Pricing<\/strong><\/li>\n<\/ol>\n<p>Tying payment to clinical outcomes\u2014such as installment-based payments or <a href=\"https:\/\/www.ohe.org\/publications\/use-pay-performance-drugs-can-it-improve-incentives-innovation\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">pay-for-performance<\/a> contracts\u2014 can ensure that pricing reflects actual clinical outcomes while distributing financial risk more equitably among payers.<\/p>\n<ol start=\"2\">\n<li><strong> Transparent R&amp;D Costing<\/strong><\/li>\n<\/ol>\n<p>Mandatory <a href=\"https:\/\/tax.thomsonreuters.com\/news\/democratic-bill-would-require-disclosure-of-pharma-rd-expenditures\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">public disclosure of R&amp;D expenditures<\/a> and subsidies could reduce price inflation and enable more informed negotiations.<\/p>\n<ol start=\"3\">\n<li><strong> Collaborative R&amp;D and Risk Sharing<\/strong><\/li>\n<\/ol>\n<p>Initiatives like the <a href=\"https:\/\/www.agencyiq.com\/blog\/new-regulatory-playbook-from-fda-supported-bespoke-gene-therapy-consortium-aims-to-accelerate-development\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">NIH\u2019s Bespoke Gene Therapy Consortium<\/a> demonstrate how public-private partnerships can reduce development risk and cut prices by up to 40%.<\/p>\n<ol start=\"4\">\n<li><strong> Global Procurement and Tiered Pricing<\/strong><\/li>\n<\/ol>\n<p>Multinational joint procurement agreements can pool demand and enhance bargaining power. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39333302\/\">Equity-based pricing<\/a>\u2014like the pricing of Zolgensma at $420,000 in Thailand vs. $2.1 million in the U.S.\u2014illustrates the feasibility of adapting prices to local economic contexts.<\/p>\n<ol start=\"5\">\n<li><strong> Clinical Trial Innovation<\/strong><\/li>\n<\/ol>\n<p>Innovative trial designs (e.g., <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10476732\/\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">basket trials<\/a>) and digital recruitment platforms can streamline development and expand access while lowering costs.<\/p>\n<h2>Evidence Gaps and the Need for Better Data<\/h2>\n<p>Economic evaluations of orphan drugs remain sparse and methodologically inconsistent. A <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01370-2\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">2024 umbrella review<\/a> found that most cost-effectiveness studies were of low or moderate quality. Without robust data on disease progression, indirect costs, and long-term outcomes, policymakers struggle to justify high prices or assess long-term value.<\/p>\n<p>Real-world evidence (RWE) must be prioritized to fill these gaps. Public registries, standardized outcomes, and post-market surveillance are essential tools for future policy coherence.<\/p>\n<h2>Toward a Global Compact on Rare Disease Innovation<\/h2>\n<p>The <a href=\"https:\/\/www.who.int\/news\/item\/24-05-2025-seventy-eighth-world-health-assembly---daily-update--24-may-2025\" target=\"_blank\" rel=\"noopener nofollow noreferrer\">World Health Organization\u2019s 2025<\/a> Rare Disease Framework calls for coordinated international action, emphasizing ethical pricing, inclusive access, and sustainable innovation. A new paradigm\u2014rooted in risk-sharing partnerships, transparent cost reporting, and equity-based pricing\u2014is not just desirable but essential.<\/p>\n<p>The proposed framework could incorporate<\/p>\n<ul>\n<li>Governments co-funding early R&amp;D in exchange for price caps post-approval<\/li>\n<li>Public disclosure of RWE to support better reimbursement decisions<\/li>\n<li>Global differential pricing based on national income and disease burden<\/li>\n<li>Offering zero\u2011interest EMI plans for high\u2011cost drugs, allowing patients to pay small instalments monthly instead huge amounts upfront<\/li>\n<\/ul>\n<p>The orphan drug economy reflects the best and worst of biomedical progress: miraculous breakthroughs shadowed by mounting inequities. As the market races in value, the stakes are clear. Left unchecked, pricing models risk exclusion\u2014curing disease for some while leaving others behind. The path forward must blend science with conscience. Balancing the imperatives of innovation, access, and equity will require bold policy, collaborative vision, and moral clarity.<\/p>\n<p><strong>References:<\/strong><\/p>\n<ol>\n<li>AgencyIQ. 2024. &#8220;New Regulatory Playbook from FDA-Supported Bespoke Gene Therapy Consortium Aims to Accelerate Development.&#8221; <em>AgencyIQ Blog<\/em>. <a href=\"https:\/\/www.agencyiq.com\/blog\/new-regulatory-playbook-from-fda-supported-bespoke-gene-therapy-consortium-aims-to-accelerate-development\/\">https:\/\/www.agencyiq.com\/blog\/new-regulatory-playbook-from-fda-supported-bespoke-gene-therapy-consortium-aims-to-accelerate-development\/<\/a>.<\/li>\n<li>Flanigan, Kimberly M., Holly L. Peay, Samantha L. Parker, and Barbara B. Biesecker. 2023. &#8220;Understanding Patient Experiences with Rare Diseases: A Qualitative Review of the Literature.&#8221; <em>Journal of Genetic Counseling<\/em> 32 (4): 746\u2013758. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10476732\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10476732\/<\/a>.<\/li>\n<li>Forsythe, Laura P., Elizabeth A. DiNenno, Sarah A. Birken, and Gila Neta. 2024. &#8220;Enhancing Patient-Centered Outcomes Research through Partnership with Rare Disease Communities.&#8221; <em>Health Affairs<\/em> 43 (1): 53\u201362. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39333302\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39333302\/<\/a>.<\/li>\n<li>Office of Health Economics. 2024. &#8220;The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?&#8221; <em>OHE<\/em>. <a href=\"https:\/\/www.ohe.org\/publications\/use-pay-performance-drugs-can-it-improve-incentives-innovation\/\">https:\/\/www.ohe.org\/publications\/use-pay-performance-drugs-can-it-improve-incentives-innovation\/<\/a>.<\/li>\n<li>Rubin, Richard. 2024. &#8220;Democratic Bill Would Require Disclosure of Pharma R&amp;D Expenditures.&#8221; <em>Thomson Reuters Tax &amp; Accounting News<\/em>. <a href=\"https:\/\/tax.thomsonreuters.com\/news\/democratic-bill-would-require-disclosure-of-pharma-rd-expenditures\/\">https:\/\/tax.thomsonreuters.com\/news\/democratic-bill-would-require-disclosure-of-pharma-rd-expenditures\/<\/a>.<\/li>\n<li>Towse, Adrian, Jorge Mestre-Ferrandiz, and Mike Drummond. 2024. &#8220;The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?&#8221; <em>PharmacoEconomics<\/em> 42: 455\u2013467. <a href=\"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01370-2\">https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01370-2<\/a>.<\/li>\n<li>World Health Organization. 2025. &#8220;Seventy-Eighth World Health Assembly\u2014Daily Update, 24 May 2025.&#8221; <em>WHO<\/em>. May 24, 2025. <a href=\"https:\/\/www.who.int\/news\/item\/24-05-2025-seventy-eighth-world-health-assembly---daily-update--24-may-2025\">https:\/\/www.who.int\/news\/item\/24-05-2025-seventy-eighth-world-health-assembly&#8212;daily-update&#8211;24-may-2025<\/a>.<\/li>\n<\/ol>\n<p><strong>Author:<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1275 size-thumbnail alignleft\" src=\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/02\/Rebecca_profile-img-1-e1739861336154-150x150.jpg\" alt=\"\" width=\"150\" height=\"150\" \/><\/p>\n<h4><strong><a href=\"https:\/\/lifesciences.enago.com\/blogs\/authors\/dr-rebecca-dsouza\" target=\"_blank\" rel=\"noopener noreferrer\">Rebecca D&#8217;souza, PhD.<\/a><\/strong><\/h4>\n<p>Associate Content Expert, Enago Academy<br \/>\nConnect with Rebecca on<strong><a href=\"https:\/\/www.linkedin.com\/in\/rebecca-dsouza31\/\" target=\"_blank\" rel=\"noopener noreferrer\"> LinkedIn<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Orphan drugs are scientifically powerful\u2014but financially overwhelming. Access is nearly nonexistent in LMICs due to high costs and import barriers. Ethical tensions include affordability, fairness, and healthcare prioritization. Policy solutions: value-based pricing, public-private R&amp;D, and income-based pricing. Better data and real-world evidence are essential for fair pricing and access. A global compact is [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1410,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[4],"tags":[15],"class_list":["post-1399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medical-education","tag-our-views"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases | Enago Lifesciences Blog<\/title>\n<meta name=\"description\" content=\"Explore the economic and ethical complexities of rare disease treatment, where life-saving orphan drugs offer hope but come with million-dollar price tags.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases | Enago Lifesciences Blog\" \/>\n<meta property=\"og:description\" content=\"Explore the economic and ethical complexities of rare disease treatment, where life-saving orphan drugs offer hope but come with million-dollar price tags.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases\" \/>\n<meta property=\"og:site_name\" content=\"Enago Lifesciences Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T10:41:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-31T16:05:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/ELS-FeatureImage-24.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"430\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"lifesciences_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"lifesciences_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases\"},\"author\":{\"name\":\"lifesciences_admin\",\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/#\\\/schema\\\/person\\\/43693a16c18ba04da631be34d38a7e75\"},\"headline\":\"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases\",\"datePublished\":\"2025-06-16T10:41:37+00:00\",\"dateModified\":\"2025-07-31T16:05:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases\"},\"wordCount\":1391,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ELS-FeatureImage-24.png\",\"keywords\":[\"Our Views\"],\"articleSection\":[\"Medical Education\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases\",\"url\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases\",\"name\":\"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases | Enago Lifesciences Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ELS-FeatureImage-24.png\",\"datePublished\":\"2025-06-16T10:41:37+00:00\",\"dateModified\":\"2025-07-31T16:05:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/#\\\/schema\\\/person\\\/43693a16c18ba04da631be34d38a7e75\"},\"description\":\"Explore the economic and ethical complexities of rare disease treatment, where life-saving orphan drugs offer hope but come with million-dollar price tags.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage\",\"url\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ELS-FeatureImage-24.png\",\"contentUrl\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ELS-FeatureImage-24.png\",\"width\":750,\"height\":430,\"caption\":\"orphan drugs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/#website\",\"url\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/\",\"name\":\"Enago Lifesciences Blog\",\"description\":\"Enago Life Sciences - Healthcare &amp; Medical Communication Agency\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/#\\\/schema\\\/person\\\/43693a16c18ba04da631be34d38a7e75\",\"name\":\"lifesciences_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cf4dd489cdff05e12a1fb39951d913d61eed36fdbf73b0e9700fa744a3723f56?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cf4dd489cdff05e12a1fb39951d913d61eed36fdbf73b0e9700fa744a3723f56?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cf4dd489cdff05e12a1fb39951d913d61eed36fdbf73b0e9700fa744a3723f56?s=96&d=mm&r=g\",\"caption\":\"lifesciences_admin\"},\"sameAs\":[\"https:\\\/\\\/lifesciences.enago.com\\\/medical-writing\\\/\"],\"url\":\"https:\\\/\\\/lifesciences.enago.com\\\/blogs\\\/author\\\/lifesciences_admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases | Enago Lifesciences Blog","description":"Explore the economic and ethical complexities of rare disease treatment, where life-saving orphan drugs offer hope but come with million-dollar price tags.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases","og_locale":"en_US","og_type":"article","og_title":"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases | Enago Lifesciences Blog","og_description":"Explore the economic and ethical complexities of rare disease treatment, where life-saving orphan drugs offer hope but come with million-dollar price tags.","og_url":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases","og_site_name":"Enago Lifesciences Blog","article_published_time":"2025-06-16T10:41:37+00:00","article_modified_time":"2025-07-31T16:05:58+00:00","og_image":[{"width":750,"height":430,"url":"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/ELS-FeatureImage-24.png","type":"image\/png"}],"author":"lifesciences_admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"lifesciences_admin","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#article","isPartOf":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases"},"author":{"name":"lifesciences_admin","@id":"https:\/\/lifesciences.enago.com\/blogs\/#\/schema\/person\/43693a16c18ba04da631be34d38a7e75"},"headline":"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases","datePublished":"2025-06-16T10:41:37+00:00","dateModified":"2025-07-31T16:05:58+00:00","mainEntityOfPage":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases"},"wordCount":1391,"commentCount":0,"image":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage"},"thumbnailUrl":"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/ELS-FeatureImage-24.png","keywords":["Our Views"],"articleSection":["Medical Education"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases","url":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases","name":"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases | Enago Lifesciences Blog","isPartOf":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage"},"image":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage"},"thumbnailUrl":"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/ELS-FeatureImage-24.png","datePublished":"2025-06-16T10:41:37+00:00","dateModified":"2025-07-31T16:05:58+00:00","author":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/#\/schema\/person\/43693a16c18ba04da631be34d38a7e75"},"description":"Explore the economic and ethical complexities of rare disease treatment, where life-saving orphan drugs offer hope but come with million-dollar price tags.","breadcrumb":{"@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#primaryimage","url":"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/ELS-FeatureImage-24.png","contentUrl":"https:\/\/lifesciences.enago.com\/blogs\/wp-content\/uploads\/2025\/06\/ELS-FeatureImage-24.png","width":750,"height":430,"caption":"orphan drugs"},{"@type":"BreadcrumbList","@id":"https:\/\/lifesciences.enago.com\/blogs\/the-cost-of-compassion-drug-pricing-and-the-economics-of-rare-diseases#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lifesciences.enago.com\/blogs\/"},{"@type":"ListItem","position":2,"name":"The Cost of Compassion: Drug Pricing and the Economics of Rare Diseases"}]},{"@type":"WebSite","@id":"https:\/\/lifesciences.enago.com\/blogs\/#website","url":"https:\/\/lifesciences.enago.com\/blogs\/","name":"Enago Lifesciences Blog","description":"Enago Life Sciences - Healthcare &amp; Medical Communication Agency","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lifesciences.enago.com\/blogs\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lifesciences.enago.com\/blogs\/#\/schema\/person\/43693a16c18ba04da631be34d38a7e75","name":"lifesciences_admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/cf4dd489cdff05e12a1fb39951d913d61eed36fdbf73b0e9700fa744a3723f56?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/cf4dd489cdff05e12a1fb39951d913d61eed36fdbf73b0e9700fa744a3723f56?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cf4dd489cdff05e12a1fb39951d913d61eed36fdbf73b0e9700fa744a3723f56?s=96&d=mm&r=g","caption":"lifesciences_admin"},"sameAs":["https:\/\/lifesciences.enago.com\/medical-writing\/"],"url":"https:\/\/lifesciences.enago.com\/blogs\/author\/lifesciences_admin"}]}},"_links":{"self":[{"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/posts\/1399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/comments?post=1399"}],"version-history":[{"count":7,"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/posts\/1399\/revisions"}],"predecessor-version":[{"id":1492,"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/posts\/1399\/revisions\/1492"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/media\/1410"}],"wp:attachment":[{"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/media?parent=1399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/categories?post=1399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifesciences.enago.com\/blogs\/wp-json\/wp\/v2\/tags?post=1399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}